X-ray Contrast Imaging Agent (e.g., Computed Tomography, Angiography, Etc.) Patents (Class 424/9.4)
  • Publication number: 20140178296
    Abstract: The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.
    Type: Application
    Filed: December 6, 2013
    Publication date: June 26, 2014
    Applicant: Georgetown University
    Inventors: Esther H. CHANG, Kathleen F. Pirollo
  • Patent number: 8753620
    Abstract: According to an aspect of the invention, injectable bulking compositions are provided which contain the following: (a) fibers that are configured to prevent migration to locations in the body remote from the injection site, for example, because they have a minimum length that is sufficiently large to prevent migration of the fibers and/or because they have surface features that stimulate host tissue response to lock the fibers in position and (b) a carrier in an amount effective to render the composition injectable.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: June 17, 2014
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Jianmin Li, Michael Madden
  • Patent number: 8753610
    Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: June 17, 2014
    Assignee: ArmaGen Technologies, Inc.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Publication number: 20140161725
    Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
    Type: Application
    Filed: September 5, 2012
    Publication date: June 12, 2014
    Applicants: Arizona Board Of Regents on Behalf of the University of Arizona, H. Lee Moffitt Cancer Center and Research Instutute, Inc.
    Inventors: David L. Morse, Robert J. Gillies, Amanda Huynh, Josef Vagner
  • Patent number: 8747812
    Abstract: An aqueous negative contrast agent for CT imaging of the gastrointestinal tract and the preparation method thereof. The agent is used in biological and pharmaceutical field. Its components and the weight percent are: hydrogel matrix 0.01-1%, micro-/nano-particles of the materials with low densities 5-50%, stabilization agents 0.1-5%, the rest is deionized water. The preparation method is: stabilization agents are added into the hydrogel matrix made of natural or synthetic hydrophilic polymers, then micro-/nano-particles of the materials with low CT densities are added or prepared, and uniformly dispersed in the hydrogel matrix. The CT density of the resulted aqueous negative contrast agent for CT imaging of the gastrointestinal tract is ?30 HU to ?500 HU. It can decrease the CT density inside the intestine lumen to lower than ?30 HU. The intestine wall can be depicted clearly and the CT signals intensities inside lumen are uniform.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: June 10, 2014
    Inventors: Xiaohui Wei, Jianrong Xu, Yuhong Xu
  • Publication number: 20140154183
    Abstract: What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
    Type: Application
    Filed: February 5, 2014
    Publication date: June 5, 2014
    Inventors: Matthias FRIEBE, Heribert SCHMITT-WILLICH, Matthias BERNDT, Ludger DINKELBORG, Norman KOGLIN, Keith GRAHAM
  • Publication number: 20140140933
    Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
    Type: Application
    Filed: November 1, 2013
    Publication date: May 22, 2014
    Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
  • Patent number: 8728529
    Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: May 20, 2014
    Assignee: General Electric Company
    Inventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, Jr., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino
  • Publication number: 20140134103
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: December 6, 2013
    Publication date: May 15, 2014
    Applicants: University of Tennessee Research Foundation, Elan Pharmaceuticals, Inc.
    Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José Saldanha
  • Patent number: 8722019
    Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 13, 2014
    Assignee: biOasis Technologies, Inc.
    Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
  • Publication number: 20140127136
    Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain.
    Type: Application
    Filed: January 9, 2014
    Publication date: May 8, 2014
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Daryl C. Drummond, Dmitri Kirpotin
  • Patent number: 8709384
    Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: April 29, 2014
    Assignee: Biosphere Medical, S.A.
    Inventor: Philippe Reb
  • Patent number: 8691186
    Abstract: The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: April 8, 2014
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Chetan Bettegowda, Catherine Foss, Shibin Zhou, Kenneth Kinzler, Bert Vogelstein
  • Patent number: 8691189
    Abstract: The present disclosure describes techniques used for colorectal cancer detection. Position and distribution of colorectal cancer tumor are detected through nuclear imaging. Alternatively, stage of colorectal cancer is identified by shading value in tumor. Thus, the present disclosure provides a safe and noninvasive clinical method for diagnosing and tracing level and distribution of colorectal cancer before and after treatment.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: April 8, 2014
    Assignee: Institute of Nuclear Energy Research, Atomic Energy Council
    Inventors: Siao-Syun Guan, Chun-Chia Cheng, Shui-Cheng Lee, Hsien-Ming Wu
  • Patent number: 8679460
    Abstract: The present invention generally relates to nonionic x-ray contrast media formulations, radiological compositions containing such agents and methods for x-ray visualization utilizing such compositions. The invention especially relates to injectable radiological compositions for x-ray visualization comprising a pharmaceutically acceptable vehicle and a mixture of a monomer, being a triiodo-substituted benzene nucleus, and a dimer, being two linked triiodo-substituted benzene nuclei, such that the mixture demonstrates favorable properties.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: March 25, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Muthunadar P. Periasamy, Brian D. Doty
  • Patent number: 8672965
    Abstract: The invention relates to novel polyvinyl alcohol (PVA) gels which gelate in situ and are suitable for nucleus (gel bodies of the intervertebral disks) replacement, and to a process and to an apparatus for administration thereof, to the use thereof and to a vessel which comprises an inventive PVA gel.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: March 18, 2014
    Assignee: InnoGEL AG
    Inventors: Rolf Mueller, Federico Innerebner, Thomas Steffen, Norbert Boos
  • Publication number: 20140072513
    Abstract: The present invention relates to degradable polyacetal polymers having a C(O)—(CH2CH2O)n—R5 or a saccharide attached to amine radical of the backbone of the polymer, their polymer-active agent conjugates and their preparation processes, to compositions, and hydrogels containing them, as well as their use in therapy, diagnostic imaging and cosmetics.
    Type: Application
    Filed: April 3, 2012
    Publication date: March 13, 2014
    Inventor: Oscar Peña Gulin
  • Publication number: 20140072514
    Abstract: The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 13, 2014
    Applicant: W. L. Gore & Associates, Inc.
    Inventors: Robert L. Cleek, Edward H. Cully, Paul D. Drumheller, Theresa A. Holland
  • Publication number: 20140065074
    Abstract: A method of tracking growth and metastasis of specific cells in vivo is disclosed. The method of the disclosure includes culturing the specific cells in a medium containing 0.1 ?M to 10 mM nanoparticles as a biomarker for X-rays, such that the specific cells carry the nanoparticles, administering the specific cells carrying the nanoparticles to a subject, irradiating the subject by an X-ray source, and determining the growth and metastasis of the specific cells by X-ray images of the nanoparticles in the subject.
    Type: Application
    Filed: August 31, 2013
    Publication date: March 6, 2014
    Applicant: ACADEMIA SINICA
    Inventors: Yeu-Kuang Hwu, Chia-Chi Chien
  • Patent number: 8663598
    Abstract: One embodiment of the disclosure provides an amino sequence of an anti-human transferrin receptor antibody, including: an amino sequence of a heavy chain variable region which is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: March 4, 2014
    Assignee: Industrial Technology Research Institute
    Inventors: Ming-Hua Yang, Min-Yuan Chou, Hsiang-Ching Wang
  • Publication number: 20140056815
    Abstract: Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells.
    Type: Application
    Filed: November 1, 2013
    Publication date: February 27, 2014
    Inventor: Gholam A. Peyman
  • Publication number: 20140056816
    Abstract: Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. Applications include a method of treating a patient with a pharmaceutically acceptable implant system comprising implanting a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles, wherein the collection comprises a plurality of sets of the particles, with the sets having different rates of biodegradation.
    Type: Application
    Filed: January 25, 2013
    Publication date: February 27, 2014
    Applicant: INCEPT, LLC
    Inventors: Patrick Campbell, Amarpreet S. Sawhney
  • Publication number: 20140056820
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.
    Type: Application
    Filed: September 30, 2013
    Publication date: February 27, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Chang Soo Hong, Tohru Yamada, Arsenio M Fialho
  • Publication number: 20140056808
    Abstract: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.
    Type: Application
    Filed: November 29, 2011
    Publication date: February 27, 2014
    Applicant: NovelMed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Publication number: 20140050669
    Abstract: The present invention provides methods of imaging dental tissue. More particularly, the invention relates to a method of imaging dental caries by administering a topical intra-oral composition that provides enhanced radiographic imaging.
    Type: Application
    Filed: May 4, 2012
    Publication date: February 20, 2014
    Applicant: CREIGHTON UNIVERSITY
    Inventor: Douglas K. Benn
  • Publication number: 20140037554
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Application
    Filed: September 9, 2013
    Publication date: February 6, 2014
    Applicant: The Boad of Trustees of the University of Illinois
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
  • Publication number: 20140037552
    Abstract: The invention relates to a Prussian Blue based nanoparticle comprising a Prussian Blue based metal core doped with one or more metal isotope and an organic biocompatible coating. The invention relates furthermore to a process for the preparation of said nanoparticle, and the use thereof as imaging contrast material or in the therapy.
    Type: Application
    Filed: February 15, 2012
    Publication date: February 6, 2014
    Inventors: Domokos Máthé, Krisztián Szigeti
  • Patent number: 8642013
    Abstract: Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: February 4, 2014
    Inventors: Ananth Annapragada, Ravi Bellamkonda, Efstathios Karathanasis, Russell M. Lebovitz
  • Patent number: 8628751
    Abstract: The invention provides compounds, including compositions, preparations and formulations, and methods of using and making such compounds. Compounds of the present invention include pyrazine derivatives having a pyrazine core and a plurality of substituents. In some embodiments, pyrazine derivatives of the invention are pyrazine core compounds having one or more electron donating groups and one or more electron withdrawing groups optionally functionalized to provide useful optical, biological, pharmacokinetic and/or physical properties.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: January 14, 2014
    Assignee: Medi Beacon Development, LLC
    Inventors: William L. Neumann, John N. Freskos
  • Publication number: 20140010755
    Abstract: A microsphere and method for forming the same are disclosed. The microsphere includes modified cellulose and at least one of a visualization agent, a magnetic material, or a radioactive material.
    Type: Application
    Filed: September 12, 2013
    Publication date: January 9, 2014
    Applicant: Confluent Surgical, Inc.
    Inventors: Rachit Ohri, Phillip D. Blaskovich, Olga Cherniavsky
  • Patent number: 8617514
    Abstract: The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: December 31, 2013
    Assignee: Georgetown University
    Inventors: Esther H. Chang, Kathleen F. Pirollo
  • Publication number: 20130336894
    Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 19, 2013
    Inventor: Eric W. Olle
  • Publication number: 20130336889
    Abstract: A nanoparticle for detecting or treating a tumor is provided. The nanoparticle includes a plurality of polymer backbones and at least one first detectable substance, of which each of the polymer backbones includes a hydrophobic region, a hydrophilic region and a chelating region, and the first detectable substance is bound to the chelating region of the polymer backbone. The hydrophobic regions of the polymer backbones form a core block, and the hydrophilic regions of the polymer backbones form a shell block surrounding the core block. A method for detecting or treating a tumor using the nanoparticle is also provided.
    Type: Application
    Filed: June 14, 2012
    Publication date: December 19, 2013
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Ming-Jium Shieh, Cheng-Liang Peng, Tsai-Yueh Luo
  • Publication number: 20130336893
    Abstract: The present invention relates to exendin-4 peptide analogues and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: June 13, 2013
    Publication date: December 19, 2013
    Applicant: SANOFI
    Inventors: Torsten HAACK, Andreas EVERS, Michael WAGNER, Bernd HENKEL, Siegfried STENGELIN
  • Publication number: 20130295021
    Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: October 11, 2011
    Publication date: November 7, 2013
    Inventors: Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Roger Nitsch, Christoph Hock
  • Publication number: 20130295018
    Abstract: The present invention provides a liquid preparation for oral administration that is capable of reducing the amount of colonic irrigation solution taken during gastrointestinal pretreatment and decreasing the burden on the subject without sacrificing test accuracy and without prolonging the time required for pretreatment, and a composition for gastrointestinal radiography used to prepare the liquid preparation for oral administration. Namely, provided are a liquid preparation for oral administration taken during gastrointestinal imaging by CT colonography that comprises an iodine compound and a water-soluble polymer or saline laxative, wherein 300 mL to 1200 mL are taken on the day before CT colonography in a single administration or divided among several administrations, and a composition for gastrointestinal radiography comprising an iodine compound and a water-soluble polymer or saline laxative, wherein 300 mL to 1200 mL are taken in the form of an aqueous solution, having an iodine content of 3.
    Type: Application
    Filed: April 4, 2013
    Publication date: November 7, 2013
    Inventors: Takehiko Motoyama, Koichi Nagata, Tetsuro Honda
  • Patent number: 8574550
    Abstract: In accordance with the present invention, a high intensity radiopaque contrast agent is disclosed. The agent may be coated on or incorporated within bulk materials, which may then be subsequently utilized to fabricate a radiopaque medical device. Primary effects through chemistry include higher radiopaque concentrations per unit weight of the radiopaque element or agent. Secondary effects include selective placement of the radiopaque elements which may further enhance the radiopacity of the device with reduced requirements of the radiopaque agent. Such a radiopaque contrast agent may be produced in various forms such as a dendrimer and/or incorporated as the end groups of polymeric chain. In addition one can incorporate biological and/or pharmaceutical agents in combination with the present invention.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: November 5, 2013
    Inventor: Jonathon Z. Zhao
  • Patent number: 8574551
    Abstract: The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted cyclodextrin, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the cyclodextrin is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: November 5, 2013
    Assignee: Verrow Pharmaceuticals, Inc.
    Inventor: Vernon D. Rowe
  • Publication number: 20130287697
    Abstract: A pharmaceutical microparticle for embolization is disclosed, which includes: a thermoresponsive polymer, an enhancer, a contrast agent, and a solvent. The particle size of pharmaceutical microparticle for embolization is 100-750 ?m. The pharmaceutical microparticle for embolization of the present invention is an effective drug carrier, and has biodegradable and X-ray imaging properties.
    Type: Application
    Filed: February 4, 2013
    Publication date: October 31, 2013
    Applicant: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Xi-Zhang LIN, Hong-Ming TSAI, Yi-Sheng LIU, Chueh-Kuan WANG, Tzong-Shyng LEU, Ping-Hen CHEN, Li-Jhen WANG, Po-Hsun TSENG, Yu-Han LI, Chiung-Yu CHEN
  • Publication number: 20130287698
    Abstract: Sympathetic nerves run through the adventitia surrounding renal arteries and are critical in the modulation of systemic hypertension. Hyperactivity of these nerves can cause renal hypertension, a disease prevalent in 30-40% of the adult population. Hypertension can be treated with neuromodulating agents (such as angiotensin converting enzyme inhibitors, angiotensin II inhibitors, or aldosterone receptor blockers), but requires adherence to strict medication regimens and often does not reach target blood pressure threshold to reduce risk of major cardiovascular events. A minimally invasive solution is presented here to reduce the activity of the sympathetic nerves surrounding the renal artery by locally delivering neurotoxic or nerve-blocking agents into the adventitia. Extended elution of these agents may also be accomplished in order to tailor the therapy to the patient.
    Type: Application
    Filed: May 16, 2013
    Publication date: October 31, 2013
    Inventor: Kirk Patrick Seward
  • Patent number: 8562946
    Abstract: A new system accomplishes easy, interchangeable production of multiple PET radiopharmaceuticals through the use of a simplified eluant-only generator and a kit based synthesis technique employing lyophilized or freeze dried ligand. Thus, by simply switching the lyophilized ligand vial kit, any number of 62Cu-labeled radiopharmaceuticals (62Cu-ligand) can be interchangeably synthesized with only one 62Zn/62Cu generator.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: October 22, 2013
    Assignee: Proportional Technologies, Inc.
    Inventor: Jeffrey L. Lacy
  • Publication number: 20130263296
    Abstract: Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.
    Type: Application
    Filed: October 28, 2011
    Publication date: October 3, 2013
    Applicants: THE JOHNS HOPKINS UNIVERSITY, VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Martin Gilbert Pomper, Hyo-eun Bhang, Paul Fisher
  • Patent number: 8540968
    Abstract: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: September 24, 2013
    Assignee: Cellectar, Inc.
    Inventors: Jamey Weichert, Marc Longino, Anatoly Pinchuk
  • Patent number: 8535642
    Abstract: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: September 17, 2013
    Assignee: GE Healthcare AS
    Inventor: Hanno Priebe
  • Publication number: 20130230454
    Abstract: Methods for the diagnosis and treatment of ischemic spinal conditions, degenerative disc disease, back pain and/or other tissue pathologies. Patients with ischemic spine disease can be categorized into subsets that are deemed to have potential to respond to therapy. In particular, therapies are disclosed which involve stimulation of neovascularization so as to increase perfusion of spinal and other anatomies.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 5, 2013
    Applicant: CARDIOVASCULAR BIOTHERAPEUTICS, INC.
    Inventors: Vance Gardner, Hon Yu, Kenneth A. Thomas, Thomas J. Stegmann, John W. Jacobs, Tugan Muftuler, Shadfar Bahri, Edwin Anderson
  • Publication number: 20130230455
    Abstract: The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.
    Type: Application
    Filed: April 12, 2013
    Publication date: September 5, 2013
    Applicants: BloodCenter Research Foundation, Inc., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Thomas P. Stossel, Po-Shun Lee, Bonnie Dittel, Katarzyna Maresz
  • Publication number: 20130230457
    Abstract: The present invention relates to a formulation of thermosensitive liposomes, and more specifically to a formulation of liposomes comprising phospholipids and a surface active agent, wherein the liposomes support long term storage at temperatures less than or equal to about 8° C., control degradate formation to maximize product potency and release their contents at mild hyperthermic temperatures. Methods of making formulations are also described.
    Type: Application
    Filed: February 15, 2013
    Publication date: September 5, 2013
    Applicant: CELSION CORPORATION
    Inventors: Robert A. REED, Daishui SU
  • Patent number: 8518371
    Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: August 27, 2013
    Assignee: Natural Pharmacia International, Inc.
    Inventors: David Y-W Lee, Xiao-Shen Ji, James A. Raleigh
  • Publication number: 20130216479
    Abstract: Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous adducts such as, the corresponding oxime derivatives is provided. Methods of making and using the adducts in radio-labelling, molecular imaging applications, and treatment of disorders such as cancer, Crohn's disease, arthritis, atherothrombosis and plaque rupture are also provided.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 22, 2013
    Inventors: Alexander Krantz, Peng Yu
  • Publication number: 20130202535
    Abstract: The present invention relates to an X-ray visible medical device comprising a medical device and a layer bound onto the medical device, wherein the layer is composed of an X-ray contrast material or a composite of the X-ray contrast material and a biocompatible polymer. Also disclosed is a method for preparing the X-ray visible medical device.
    Type: Application
    Filed: September 17, 2012
    Publication date: August 8, 2013
    Applicant: SNU R&DB FOUNDATION
    Inventor: SNU R&DB Foundation